Oleg Nodelman
Vermogen: - $ op 31-05-2026
Vermogen: - $ op 31-05-2026
Oleg Nodelman is the founder of EcoR1 Capital, LLC, founded in 2012, where the title held is Portfolio Manager.
Current jobs include Chief Executive Officer at EcoR1 Panacea Holdings LLC; Independent Director at AnaptysBio, Inc. since 2021; Director at ReCode Therapeutics, Inc.; Director at Scorpion Therapeutics, Inc.; Director at Paratus Sciences Corp.; Non-Independent Non-Executive Director at Lakefront Biotherapeutics since 2024; Independent Director at Zymeworks, Inc. starting 2025; and Portfolio Manager at Ecor1 Capital LLC.
Former jobs include Chairman & Chief Executive Officer at Panacea Acquisition Corp.
II from 2020 to 2021; Chairman & Chief Executive Officer at Panacea Acquisition Corp.
from 2020 to 2021; Non-Executive Director at Addex Therapeutics Ltd. from 2012 to 2014; Independent Director at Nuvation Bio, Inc. from 2021 to 2023; Independent Director at Prothena Corp.
Plc from 2019 to 2024; Director at Aktis Oncology, Inc. from 2021 to 2026; Portfolio Manager at Biotechnology Value Fund LP from 2001 to 2012; and Portfolio Manager at BVF Partners LP.
Education includes an undergraduate degree from Georgetown University conferred in 1999.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
AKTIS ONCOLOGY, INC. -.--% | 12-01-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ANAPTYSBIO, INC. | Directeur/Bestuurslid | 08-04-2021 |
| LAKEFRONT BIOTHERAPEUTICS NV | Directeur/Bestuurslid | 07-10-2024 |
| ZYMEWORKS INC. | Directeur/Bestuurslid | 17-02-2025 |
Paratus Sciences Corp.
Paratus Sciences Corp. BiotechnologyHealth Technology Operates as a biotechnology company | Directeur/Bestuurslid | - |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics | Directeur/Bestuurslid | - |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops precision oncology therapies for cancer treatment | Directeur/Bestuurslid | - |
EcoR1 Panacea Holdings LLC | Algemeen Directeur | - |
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 invests (long and short) in securities, consisting principally, but not solely, of equity and equity-related securities that are issued by biotechnology companies globally. | Algemeen Directeur | 01-01-2012 |
| Bedrijven | Functie | Einde |
|---|---|---|
| AKTIS ONCOLOGY, INC. | Directeur/Bestuurslid | 20-05-2026 |
| ░░░░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 17 |
|---|---|
Biotechnology Value Fund LP
Biotechnology Value Fund LP Investment Trusts/Mutual FundsMiscellaneous Functions as a hedge fund | Miscellaneous |
BVF Partners LP
BVF Partners LP Investment ManagersFinance BVF generally pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The focus of the BVF strategy is on fundamental, bottom-up analysis of individual issuers based on the theory that market mispricing exist because market prices do not incorporate all knowable economic and other relevant data. | Finance |
Galapagos NV
Galapagos NV BiotechnologyHealth Technology Manufactures and develops pharmaceutical products for oncology | Health Technology |
AnaptysBio, Inc.
AnaptysBio, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Health Technology |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Addex Therapeutics Ltd.
Addex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs | Health Technology |
Prothena Corp. Plc
Prothena Corp. Plc BiotechnologyHealth Technology Focuses on the discovery and development of novel antibodies | Health Technology |
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 invests (long and short) in securities, consisting principally, but not solely, of equity and equity-related securities that are issued by biotechnology companies globally. | Finance |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics | Health Technology |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops precision oncology therapies for cancer treatment | Health Technology |
Panacea Acquisition Corp.
Panacea Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
EcoR1 Panacea Holdings LLC | |
Nuvation Bio, Inc.
Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Panacea Acquisition Corp. II
Panacea Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers radiopharmaceuticals to treat tumor cancers | Health Technology |
Paratus Sciences Corp.
Paratus Sciences Corp. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Zymeworks, Inc.
Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau